

Richter's syndrome - Pipeline Insight, 2021

<https://marketpublishers.com/r/R3FACEC02B59EN.html>

Date: June 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: R3FACEC02B59EN

Abstracts

This report can be delivered to the clients within 24 Hours

DelveInsight's, "Richter's syndrome - Pipeline Insight, 2021," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Richter's syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Richter's syndrome Understanding

Richter's syndrome: Overview

Richter's Syndrome (RS), also known as Richter's Transformation, is a rare complication of Chronic Lymphocytic Leukaemia (CLL) and/or Small Lymphocytic Lymphoma (SLL). It is characterised by the sudden transformation of the CLL/SLL into a significantly more aggressive form of large cell lymphoma. Richter's Syndrome occurs in approximately 2-10% of all CLL/SLL patients during the course of their disease.

The most common symptoms of Richter's Syndrome arise from a sudden and dramatic increase in the size of lymph nodes (also known as 'lymphadenopathy') characterised by usually painless areas of swelling in the neck, axilla, abdomen (most commonly in the spleen, also known as 'splenomegaly') or groin. Patients also often experience a

dramatic increase in unexplained weight loss, fevers and night sweats (often collectively referred to as 'B-symptoms').

The definitive or differential diagnosis of Richter's Syndrome is achieved by an excisional biopsy or CT/ultrasound guided core needle biopsy of an enlarged lymph node that is thought to be indicative of the Richter's transformation. The current standard first-line treatment for this type of lymphoma is the immuno-chemotherapy using a combination of chemo drugs and a targeted anti-CD 20 monoclonal antibody. Other second-line chemotherapy regimens often used to treat this type of lymphoma (if non-responsive or 'refractory' to R-CHOP) include R-ICE, D-HAC, R-DHAP, GIVE, etc.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Richter's syndrome R&D. The therapies under development are focused on novel approaches for Richter's syndrome.

Richter's syndrome Emerging Drugs Chapters

This segment of the Richter's syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Richter's syndrome Emerging Drugs

Duvelisib: Secura Bio

Duvelisib, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. It is currently in Phase II stage of development for the treatment of Richter's syndrome and is being developed by Secura Bio.

Further product details are provided in the report..

Richter's syndrome: Therapeutic Assessment

This segment of the report provides insights about the different Richter's syndrome drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Richter's syndrome

There are approx. 5+ key companies which are developing the Richter's syndrome. The companies which have their Richter's syndrome drug candidates in the most advanced stage, i.e. Phase II include, Secura Bio.

Phases

DelveInsight's report covers around 5+ products under different phases of clinical development like

Late-stage products (Phase III)

Mid-stage products (Phase II)

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Richter's syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Richter's syndrome: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Richter's syndrome therapeutic drugs

key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Richter's syndrome drugs.

Richter's syndrome Report Insights

- Richter's syndrome Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

Richter's syndrome Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

- How many companies are developing Richter's syndrome drugs?

- How many Richter's syndrome drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for Richter's syndrome?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Richter's syndrome therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Richter's syndrome and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

TG Therapeutics

Secura Bio

AstraZeneca

Vincerx Pharma

Merck & Co

Key Products

Umbralisib

Duvelisib

AZD4573

VIP152

MK-1026

Contents

Introduction

Executive Summary

Richter's syndrome: Overview

Structure

Mechanism of Action

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Richter's syndrome– DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Richter's syndrome companies' collaborations, Licensing, Acquisition -Deal Value

Trends

Richter's syndrome Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Drug Name: Company Name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report..

Mid Stage Products (Phase II)

Comparative Analysis

Duvelisib: Secura Bio

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report..

Early Stage Products (Phase I)

Comparative Analysis

AZD4573: AstraZeneca

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report..

Preclinical and Discovery Stage Products

Comparative Analysis

Drug Name: Company Name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report..

Inactive Products

Comparative Analysis

Richter's syndrome Key Companies

Richter's syndrome Key Products

Richter's syndrome- Unmet Needs

Richter's syndrome- Market Drivers and Barriers

Richter's syndrome- Future Perspectives and Conclusion

Richter's syndrome Analyst Views

Richter's syndrome Key Companies

Appendix

List Of Tables

LIST OF TABLES

- Table 1 Total Products for Richter's syndrome
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Richter's syndrome
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Richter's syndrome - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/R3FACEC02B59EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R3FACEC02B59EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970